Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADOCY OTCMKTS:CYYNF NASDAQ:IMMX NASDAQ:KLRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADOCYAdocia$11.80$11.80$9.80▼$11.80$215.70M-0.2N/AN/ACYYNFCynata Therapeutics$0.12$0.12$0.08▼$0.15$21.20M-0.33N/AN/AIMMXImmix Biopharma$2.64+0.6%$2.22$1.34▼$3.20$87.89M0.23193,914 shs199,964 shsKLRSKalaris Therapeutics$4.84-1.8%$4.28$2.14▼$24.15$90.51M0.42131,125 shs1,617 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADOCYAdocia0.00%0.00%0.00%0.00%0.00%CYYNFCynata Therapeutics0.00%0.00%0.00%+47.50%-37.89%IMMXImmix Biopharma+5.65%+3.15%+25.36%-10.27%+78.23%KLRSKalaris Therapeutics-3.33%-25.19%+32.88%+103.72%+492,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADOCYAdocia$11.80$11.80$9.80▼$11.80$215.70M-0.2N/AN/ACYYNFCynata Therapeutics$0.12$0.12$0.08▼$0.15$21.20M-0.33N/AN/AIMMXImmix Biopharma$2.64+0.6%$2.22$1.34▼$3.20$87.89M0.23193,914 shs199,964 shsKLRSKalaris Therapeutics$4.84-1.8%$4.28$2.14▼$24.15$90.51M0.42131,125 shs1,617 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADOCYAdocia0.00%0.00%0.00%0.00%0.00%CYYNFCynata Therapeutics0.00%0.00%0.00%+47.50%-37.89%IMMXImmix Biopharma+5.65%+3.15%+25.36%-10.27%+78.23%KLRSKalaris Therapeutics-3.33%-25.19%+32.88%+103.72%+492,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADOCYAdocia 0.00N/AN/AN/ACYYNFCynata Therapeutics 0.00N/AN/AN/AIMMXImmix Biopharma 2.00Hold$8.00203.61% UpsideKLRSKalaris Therapeutics 2.33Hold$3.00-38.02% DownsideCurrent Analyst Ratings BreakdownLatest CYYNF, KLRS, ADOCY, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025IMMXImmix BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KLRSKalaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025IMMXImmix BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KLRSKalaris TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/12/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.009/2/2025KLRSKalaris TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy8/25/2025IMMXImmix BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/23/2025KLRSKalaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$3.007/23/2025KLRSKalaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$3.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADOCYAdocia$13.12M16.44N/AN/A($0.21) per share-56.19CYYNFCynata TherapeuticsN/AN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$22.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADOCYAdocia-$10.09MN/A0.00∞N/AN/AN/AN/AN/ACYYNFCynata TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AIMMXImmix Biopharma-$21.61M-$0.77N/AN/AN/AN/A-205.35%-110.63%11/11/2025 (Estimated)KLRSKalaris Therapeutics-$58.77MN/A0.00∞N/AN/A-81.02%-65.15%N/ALatest CYYNF, KLRS, ADOCY, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025IMMXImmix Biopharma-$0.19N/AN/AN/AN/AN/A8/13/2025Q2 2025KLRSKalaris Therapeutics-$0.51-$0.61-$0.10-$0.61N/AN/A8/8/2025Q1 2025IMMXImmix Biopharma-$0.21-$0.22-$0.01-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADOCYAdociaN/AN/AN/AN/AN/ACYYNFCynata TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADOCYAdociaN/AN/AN/ACYYNFCynata TherapeuticsN/AN/AN/AIMMXImmix BiopharmaN/A1.231.23KLRSKalaris TherapeuticsN/A11.9811.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADOCYAdociaN/ACYYNFCynata TherapeuticsN/AIMMXImmix Biopharma11.26%KLRSKalaris Therapeutics66.05%Insider OwnershipCompanyInsider OwnershipADOCYAdociaN/ACYYNFCynata TherapeuticsN/AIMMXImmix Biopharma55.40%KLRSKalaris Therapeutics74.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADOCYAdocia7818.28 millionN/ANot OptionableCYYNFCynata TherapeuticsN/A179.63 millionN/ANot OptionableIMMXImmix Biopharma933.04 million14.73 millionOptionableKLRSKalaris Therapeutics11018.70 million4.68 millionN/ACYYNF, KLRS, ADOCY, and IMMX HeadlinesRecent News About These CompaniesKalaris Therapeutics (NASDAQ:KLRS) Trading 7% Higher - Here's What HappenedOctober 14 at 3:13 AM | marketbeat.comKalaris Therapeutics (NASDAQ:KLRS) Receives "Sell (E)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comKalaris Therapeutics (NASDAQ:KLRS) Stock Rating Upgraded by Wall Street ZenOctober 6, 2025 | americanbankingnews.comKalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street ZenOctober 3, 2025 | marketbeat.comKalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest UpdateOctober 3, 2025 | marketbeat.comUPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationSeptember 15, 2025 | globenewswire.comKalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationSeptember 15, 2025 | globenewswire.comKalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should KnowSeptember 1, 2025 | zacks.comKalaris Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | globenewswire.comBernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. SecuritiesJune 5, 2025 | globenewswire.comKalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceJune 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYYNF, KLRS, ADOCY, and IMMX Company DescriptionsAdocia OTCMKTS:ADOCY$11.80 0.00 (0.00%) As of 10/10/2025Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.Cynata Therapeutics OTCMKTS:CYYNF$0.12 0.00 (0.00%) As of 10/13/2025Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Immix Biopharma NASDAQ:IMMX$2.64 +0.02 (+0.57%) As of 10:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Kalaris Therapeutics NASDAQ:KLRS$4.84 -0.09 (-1.83%) As of 09:46 AM EasternAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
